Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets

Harm Reduction Journal

Volumn 6, Issue , 2009, Pages

  McLean, Stuart ^a   Bruno, Raimondo ^a   Brandon, Susan ^a   de Graaff, Barbara ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE SULFATE;

ARTICLE; CONTENT ANALYSIS; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG SOLUBILITY; FILTER; FILTRATION; INFECTION RISK; LIQUID CHROMATOGRAPHY; MICROBIAL CONTAMINATION; MICROSCOPY; PARTICLE SIZE; RISK ASSESSMENT; RISK REDUCTION; SLOW RELEASE FORMULATION; TABLET FORMULATION;

EID: 74049087497     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-6-37     Document Type: Article

References (24)

1. Degenhardt L, Black E, Breen C, Bruno R, Kinner S, Roxburgh A, Fry C, Jenkinson R, Ward J, Fetherston J, et al. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006, 25:403-412. 10.1080/09595230600868504, 16939934.
2. Fischer B, Cruz MF, Rehm J. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatry 2006, 51:624-634.
3. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences 2006, Baltimore: Lippincott Williams & Wilkins, 5.
4. Roberts WC. Pulmonary talc granulomas, pulmonary fibrosis, and pulmonary hypertension resulting from intravenous injection of talc-containing drugs intended for oral use. Proc Bayl Univ Med Cent 2002, 15:260-261. 1276621, 16333448.
5. Gotway MB, Marder SR, Hanks DK, Leung JWT, Dawn SK, Gean AD, Reddy GP, Araoz PA, Webb WR. Thoracic complications of illicit drug use: An organ system approach. Radiographics 2002, 22:S119-S135.
6. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?. Pharmaceutical Research 2009, 26:235-243. 10.1007/s11095-008-9697-x, 18712584.
7. del Giudice P. Cutaneous complications of intravenous drug abuse. British Journal of Dermatology 2004, 150:1-10. 10.1111/j.1365-2133.2004.05607.x, 14746612.
8. Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am 2002, 16:697-712. 10.1016/S0891-5520(02)00017-X, 12371123.
9. Chiang W, Goldfrank L. The medical complications of drug abuse. Med J Aust 1990, 152:83-88.
10. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Ann Intern Med 1993, 119:1017-1028.
11. National Centre in HIV Epidemiology and Clinical Research Australian NSP Survey National Data Report 2004-2008. 2009, Sydney: University of New South Wales, National Centre in HIV Epidemiology and Clinical Research.
12. Stafford J, Sindicich N, Burns L, Cassar J, Cogger S, de Graaff B, George J, Moon C, Phillips B, Quinn B, White N. Australian Drug Trends 2008: Findings from the Illicit Drug Reporting System. 2009, Sydney: National Drug and Alcohol Research Centre.
13. de Graaff B, Bruno R. Tasmanian Drug Trends 2007: Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series No. 5 2008, Sydney: National Drug and Alcohol Research Centre.
14. de Graaff B, Bruno R. Tasmanian Drug Trends 2008: Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series No. 23 2009, Sydney: National Drug and Alcohol Research Centre.
15. Miller DA, DiNunzio JC, Williams RO. Advanced formulation design: Improving drug therapies for the management of severe and chronic pain. Drug Development and Industrial Pharmacy 2008, 34:117-133. 10.1080/03639040701542200, 18302030.
16. British Pharmacopoeia Commission British Pharmacopoeia 2005, London: The Stationery Office, British Pharmacopoeia Commission.
17. Thomas J. Australian Prescription Products Guide 2006, Hawthorn: Australian Pharmaceutical Publishing Co, 35.
18. Scott J. Laboratory study of the effectiveness of filters used by heroin injectors. Journal of Substance Use 2005, 10:293-301.
19. Roy SD, Flynn GL. Solubility behavior of narcotic analgesics in aqueous media - solubilities and dissociation constants of morphine, fentanyl and sufentanil. Pharmaceutical Research 1989, 6:147-151. 10.1023/A:1015932610010, 2569731.
20. Seeley RR, Stephens TD, Tate P. Anatomy and Physiology 2006, New York: McGraw Hill, 7.
21. Kang YJ. Toxic responses of the heart and vascular system. Casarett and Doull's Toxicology: The Basic Science of Poisons 2008, 699-739. New York: McGraw Medical, Klaasen CD, 7.
22. Caflisch C, Wang J, Zbinden R. The role of syringe filters in harm reduction among injection drug users. American Journal of Public Health 1999, 89:1252-1254. 10.2105/AJPH.89.8.1252, 1508672, 10432918.
23. Yuasa T, Ishikawa G, Manabe S, Sekiguchi S, Takeuchi K, Miyamura T. The particle size of hepatitis C virus estimated by filtration through microporous regenerated cellulose fibre. J Gen Virol 1991, 72(Pt 8):2021-2024. 10.1099/0022-1317-72-8-2021, 1714947.
24. Palepu A, Tyndall MW, Leon H, Muller J, O'Shaughnessy MV, Schechter MT, Anis AH. Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal 2001, 165:415-420. 81365, 11531049.